Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.62 |
| ▸ | KDM4A | O75164 | 1/20 | 0.55 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.55 |
| ▸ | KLKB1 | P03952 | 5/20 | 0.55 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.54 |
| ▸ | TSLP | Q969D9 | 7/20 | 0.54 |
| ▸ | TFPI | P10646 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25944120 | 0.95 | PCSK9 (0.57) | PCSK9KDM4ACD274KLKB1EPHA2 | |
| SCHEMBL25942530 | 0.91 | PCSK9 (0.61) | PCSK9KDM4ACD274KLKB1EPHA2 | |
| SCHEMBL23960378 | 0.89 | CD274 (0.70) | PCSK9CD274KLKB1EPHA2TSLP | |
| SCHEMBL25944356 | 0.87 | PCSK9 (0.57) | PCSK9KDM4ACD274KLKB1EPHA2 | |
| SCHEMBL23960487 | 0.86 | CD274 (0.57) | PCSK9KDM4ACD274KLKB1EPHA2 | |
| SCHEMBL25943437 | 0.86 | CD274 (0.57) | PCSK9KDM4ACD274KLKB1EPHA2 | |
| SCHEMBL25943565 | 0.85 | CD274 (0.65) | PCSK9CD274KLKB1EPHA2TSLP | |
| SCHEMBL23960488 | 0.84 | CD274 (0.65) | PCSK9KDM4ACD274KLKB1EPHA2 | |
| SCHEMBL16488478 | 0.83 | ITGB3 (0.61) | KLKB1TSLP | |
| SCHEMBL8659758 | 0.82 | KDM4A (0.65) | KDM4ATSLP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242586-A1 | RAS INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242586-A1 | RAS INHIBITORS AND USES THEREOF | KRAS, NRAS, HRAS | PCSK9 1665/4885KDM4A 3295/4885CD274 3925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.